hVIVO - hMPV Challenge Model Update
HVO Mon, 13 Jan 2025, 07:30am GMT
hVIVO plc announces that it has successfully completed a pilot characterisation study for its human metapneumovirus (hMPV) strain A2 challenge agent, demonstrating proof-of-concept for a future hVIVO hMPV challenge model to test new vaccines and antivirals.
Dr. Andrew Catchpole
Chief Scientific Officer, hVIVO
Dr. Andrew Catchpole, Chief Scientific Officer, hVIVO
Mon, 13 Jan 2025, 7:30am GMT
Dr Yamin ‘Mo’ Khan, Chief Executive Officer, hVIVO
Wed, 17 Jul 2024, 10:00am BST
Management Team, hVIVO plc
Fri, 22 Dec 2023, 11:09am GMT
Dr Yamin ‘Mo’ Khan, Chief Executive Officer, hVIVO
Wed, 2 Nov 2022, 9:30am GMT
Dr Yamin ‘Mo’ Khan, Chief Executive Officer, hVIVO
Fri, 28 Oct 2022, 1:33pm BST